| 93.67 1.92 (2.09%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 113.27 | 1-year : | 132.3 |
| Resists | First : | 96.98 | Second : | 113.27 |
| Pivot price | 91.14 |
|||
| Supports | First : | 87.73 | Second : | 82.01 |
| MAs | MA(5) : | 92.64 |
MA(20) : | 90.33 |
| MA(100) : | 81.06 |
MA(250) : | 77.21 |
|
| MACD | MACD : | 2 |
Signal : | 2 |
| %K %D | K(14,3) : | 54.9 |
D(3) : | 55.3  |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 98.4 | Low : | 55.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AXSM ] has closed below upper band by 24.0%. Bollinger Bands are 26.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 94.84 - 95.2 | 95.2 - 95.62 |
| Low: | 90.74 - 91.12 | 91.12 - 91.57 |
| Close: | 92.94 - 93.57 | 93.57 - 94.29 |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Thu, 12 Sep 2024
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Wed, 11 Sep 2024
Mark E. Saad Sells 11,016 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat
Wed, 11 Sep 2024
Axsome therapeutics director Saad sells shares worth over $1m - Investing.com
Mon, 09 Sep 2024
What Analysts Are Saying About Axsome Therapeutics Stock - Benzinga
Fri, 06 Sep 2024
Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult - Simply Wall St
Wed, 04 Sep 2024
Axsome Therapeutics Announces FDA Acceptance of NDA - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 16.8 (%) |
| Held by Institutions | 85.9 (%) |
| Shares Short | 7,670 (K) |
| Shares Short P.Month | 8,280 (K) |
| EPS | -6.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.15 |
| Profit Margin | -105.9 % |
| Operating Margin | -87.1 % |
| Return on Assets (ttm) | -28.3 % |
| Return on Equity (ttm) | -161.7 % |
| Qtrly Rev. Growth | 86.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 6.07 |
| EBITDA (p.s.) | -5.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -167 (M) |
| Levered Free Cash Flow | -77 (M) |
| PE Ratio | -14.24 |
| PEG Ratio | -0.1 |
| Price to Book value | 43.56 |
| Price to Sales | 15.42 |
| Price to Cash Flow | -26.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|